Perrigo (PRGO) Misses Q4 EPS by 3c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Perrigo Co. (PRGO) PT Lowered to $48 at RBC Capital
February 28, 2019 6:48 AM ESTRBC Capital analyst Randall Stanicky lowered the price target on Perrigo Co. (NYSE: PRGO) to $48.00 (from $50.00) while maintaining a Sector Perform rating following results.
Stanicky notes consumer margins are under pressure and they stay cautious into the May update.
... MorePerrigo (PRGO) Receives Leave To Judicially Review Irish Revenue Tax Assessment
February 25, 2019 8:39 AM ESTllPerrigo Company plc (NYSE: PRGO), a leading global provider of "Quality, Affordable, Self-Care Products", today announced that its subsidiary, Perrigo Pharma International DAC ("Elan Pharma"), has been granted leave by the Irish High Court to judicially review the November 29, 2018 issuance of a Notice of Amended Assessment by the Irish Office of the Revenue Commissioners for the calendar year ended December 31, 2013.
As... More
